Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Aug:98:39-44.
doi: 10.1016/j.phrs.2014.10.003. Epub 2014 Oct 29.

Novel therapeutic approaches for diabetic nephropathy and retinopathy

Affiliations
Review

Novel therapeutic approaches for diabetic nephropathy and retinopathy

Vera Usuelli et al. Pharmacol Res. 2015 Aug.

Abstract

Diabetes mellitus is a chronic disease that in the long-term increases the microvascular and macrovascular degenerative complications thus being responsible for a large part of death associated with diabetes. During the years, while preventive care for diabetic patients has improved, the increase in the prevalence of diabetes worldwide is continuous. The detrimental effects of diabetes mellitus result in microvascular diseases, which recognize hyperglycemia as major determinant. A significant number of potential therapeutic targets for the treatment of diabetic microvascular complications have been proposed, but the encouraging results obtained in preclinical studies, have largely failed in clinical trials. Currently, the most successful strategy to prevent microvascular complications of diabetes is the intensive treatment of hyperglycemia or the normalization of glycometabolic control achieved with pancreatic and islet transplantation. In this review, we focus on the novel therapeutic targets to prevent the development and progression of diabetic nephropathy and retinopathy microvascular complications.

Keywords: Diabetic nephropathy; Diabetic retinopathy; Hyperglycemia; Microvascular complications; Type 1 diabetes; Type 2 diabetes.

PubMed Disclaimer

MeSH terms